BIOMAT Database Logo BIOMAT Database Logo

[Antipyretic activity of SL-573 (II) (author's transl)]. 1978

Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai

Antipyretic activity of SL-573 was not influenced by age and sex difference in rats. The combined effect of other drugs on antipyretic activity of SL-573 was examined, using several drugs which might be clinically applicable. Cefazolin sodium, ampicillin sodium, codeine phosphate, hydrochlorothiazide and haloperidol did not show any significant effect on antipyretic activity of SL-573. Diazepam itself showed antipyretic activity, and its combined use with SL-573 resulted in an additive effect. SL-573 also showed antipyretic activity in mice with fever induced by yeast, as was seen in rats. SL-573 diminished the hyperthermic response to bacterial endotoxin and leucocytic pyrogen in rats, but not to 2, 4-dinitrophenol. Additionally, SL-573 did not inhibit the bacterial endotoxin-induced production of leucocytic pyrogen and its release in saline medium. SL-573, therefore, is considered to be a centrally acting antipyretic. Intraventricular injection of prostaglandin E2 and arachidonic acid induced a hyperthermia in mice. SL-573 clearly inhibited arachidonic acid-induced hyperthermia, but not prostaglandin E2-induced hyperthermia. Since SL-573 is known to inhibit prostaglandin biosynthesis from arachidonic acid, the prostaglandin biosynthesis inhibition may be one of the main mechanisms of antipyretic action of SL-573.

UI MeSH Term Description Entries
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D011749 Pyrogens Substances capable of increasing BODY TEMPERATURE and cause FEVER and may be used for FEVER THERAPY. They may be of microbial origin, often POLYSACCHARIDES, and may contaminate distilled water. Pyrogen
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D004140 Dinitrophenols Organic compounds that contain two nitro groups attached to a phenol.
D004232 Diuretics Agents that promote the excretion of urine through their effects on kidney function. Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004731 Endotoxins Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. Endotoxin
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias

Related Publications

Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
[Effect of SL-573 on several functions of rat polymorphonuclear leucocytes and mast cells (author's transl)].
January 1979, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
Inhibition of prostaglandin biosynthesis by SL-573.
April 1976, Biochemical pharmacology,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
[Antipyretic effects of lysinsalicylate VUFB (author's transl)].
July 1980, Casopis lekaru ceskych,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
[Hypocholesterolemic activity of phytosterol. II (author's transl)].
May 1980, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
[Pharmacological characterization of novel pyridazines. Part 2: Analgetic, antipyretic and antiphlogistic activity (author's transl)].
November 1981, Die Pharmazie,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
Inhibition of prostaglandin biosynthesis in rat small intestine by SL-573.
March 1978, Biochemical pharmacology,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
[Combination of antibiotics with analgesic and antipyretic substances (author's transl)].
January 1979, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Zweite naturwissenschaftliche Abteilung: Mikrobiologie der Landwirtschaft der Technologie und des Umweltschutzes,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
Antipyretic activity of some indigenous drugs. II.
July 1955, The Indian journal of medical research,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
[Antimycoplasmal compounds. II. Antimycoplasmal activity of bis-thiosemicarbazones (author's transl)].
June 1977, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Y Yanagi, and H Kurokawa, and Y Nagao, and T Inukai
[Enzymatic assay of cholinesterase activity. II. Clinical application (author's transl)].
September 1977, Rinsho byori. The Japanese journal of clinical pathology,
Copied contents to your clipboard!